Adjunct Thrombolysis Enhances Brain Reperfusion following Successful Thrombectomy.
Female
Humans
Male
Brain
/ diagnostic imaging
Brain Ischemia
/ diagnostic imaging
Cerebral Infarction
Creatine
/ therapeutic use
Endovascular Procedures
Fibrinolytic Agents
/ therapeutic use
Reperfusion
/ methods
Stroke
/ diagnostic imaging
Thrombectomy
/ methods
Thrombolytic Therapy
/ methods
Tissue Plasminogen Activator
/ therapeutic use
Treatment Outcome
Middle Aged
Aged
Aged, 80 and over
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
05
08
2022
received:
01
06
2022
accepted:
05
08
2022
pubmed:
3
9
2022
medline:
26
10
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
This study was undertaken to investigate whether adjunct alteplase improves brain reperfusion following successful thrombectomy. This single-center, randomized, double-blind, placebo-controlled study included 36 patients (mean [standard deviation] = 70.8 [13.5] years old, 18 [50%] women) with large vessel occlusion undergoing thrombectomy resulting in near-normal (expanded Thrombolysis in Cerebral Infarction [eTICI] b50/67/2c, n = 23, 64%) or normal angiographic reperfusion (eTICI 3, n = 13, 36%). Seventeen patients were randomized to intra-arterial alteplase (0.225mg/kg), and 19 received placebo. At 48 hours, patients had brain perfusion/diffusion-weighted magnetic resonance imaging (MRI) and MRI-spectroscopy. The primary outcome was the difference in the proportion of patients with areas of hypoperfusion on MRI. Secondary outcomes were the infarct expansion ratio (final to initial infarction volume), and the N-acetylaspartate (NAA) peak relative to total creatine as a marker of neuronal integrity. The prevalence of hypoperfusion was 24% with intra-arterial alteplase, and 58% with placebo (adjusted odds ratio = 0.20, 95% confidence interval [CI] = 0.04-0.91, p = 0.03). Among 14 patients with final eTICI 3 scores, hypoperfusion was found in 1 of 7 (14%) in the alteplase group and 3 of 7 (43%) in the placebo group. Abnormal brain perfusion was associated with worse functional outcome at day 90. Alteplase significantly reduced the infarct expansion ratio compared with placebo (median [interquartile range (IQR)] = 0.7 [0.5-1.2] vs 3.2 [1.8-5.7], p = 0.01) and resulted in higher NAA peaks (median [IQR] = 1.13 [0.91-1.36] vs 1.00 [0.74-1.22], p < 0.0001). There is a high prevalence of areas of hypoperfusion following thrombectomy despite successful reperfusion on angiography. Adjunct alteplase enhances brain reperfusion, which results in reduced expansion of the infarction and improved neuronal integrity. ANN NEUROL 2022;92:860-870.
Identifiants
pubmed: 36054449
doi: 10.1002/ana.26474
pmc: PMC9804472
doi:
Substances chimiques
Creatine
MU72812GK0
Fibrinolytic Agents
0
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
860-870Informations de copyright
© 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Nat Med. 2009 Sep;15(9):1031-7
pubmed: 19718040
J Cereb Blood Flow Metab. 2020 May;40(5):966-977
pubmed: 31208242
Stroke. 2014 Aug;45(8):2425-30
pubmed: 24968928
NMR Biomed. 2001 Jun;14(4):260-4
pubmed: 11410943
JAMA. 2016 Sep 27;316(12):1279-88
pubmed: 27673305
J Cereb Blood Flow Metab. 2012 Dec;32(12):2091-9
pubmed: 23047270
Sci Rep. 2020 Mar 18;10(1):4973
pubmed: 32188911
Stroke. 2020 Jun;51(6):1736-1742
pubmed: 32404034
Int J Stroke. 2019 Jan;14(1):23-31
pubmed: 30188259
Stroke. 2019 Mar;50(3):690-696
pubmed: 30777000
Stroke. 2019 Sep;50(9):2389-2395
pubmed: 31366315
Am J Pathol. 1968 Feb;52(2):437-53
pubmed: 5635861
J Cereb Blood Flow Metab. 2021 Feb;41(2):253-266
pubmed: 32960688
Neurology. 2022 Feb 22;98(8):e790-e801
pubmed: 34906976
Neuron. 2015 Jul 1;87(1):95-110
pubmed: 26119027
Stroke. 2015 Nov;46(11):3241-8
pubmed: 26443832
Stroke. 1992 May;23(5):712-8
pubmed: 1579969
Ann Neurol. 2006 Nov;60(5):508-517
pubmed: 17066483
JAMA. 2022 Mar 1;327(9):826-835
pubmed: 35143603
J Neurointerv Surg. 2019 May;11(5):433-438
pubmed: 30194109
Brain. 2020 Dec 5;143(11):3225-3233
pubmed: 33141145
Stroke. 1991 Oct;22(10):1276-83
pubmed: 1926239
Stroke. 1994 Jan;25(1):79-85
pubmed: 8266387
Am J Pathol. 1994 Sep;145(3):728-40
pubmed: 8080052
Stroke. 2003 Aug;34(8):e109-37
pubmed: 12869717
Nature. 2014 Apr 3;508(7494):55-60
pubmed: 24670647
J Neurointerv Surg. 2019 Jun;11(6):545-553
pubmed: 30389899
Transl Stroke Res. 2018 Feb;9(1):44-50
pubmed: 28825223
Neuroradiology. 2014 Feb;56(2):117-27
pubmed: 24337610
Stroke. 1986 Mar-Apr;17(2):246-53
pubmed: 3961835
Stroke. 2013 Jul;44(7):1885-90
pubmed: 23704106
Stroke. 2009 Aug;40(8):2872-4
pubmed: 19478228
Sci Rep. 2017 Sep 14;7(1):11636
pubmed: 28912596
Physiol Rev. 2007 Jan;87(1):315-424
pubmed: 17237348
J Neurointerv Surg. 2022 Sep;14(9):881-885
pubmed: 34544824
Stroke. 2013 Sep;44(9):2650-63
pubmed: 23920012